top of page
A framework to support new product introduction in national health systems
Resource Library


2024 HIV Market Report
CHAI is pleased to release the fifteenth issue of our annual HIV market report. The 2024 HIV Market Report provides a detailed look at...
Dec 4, 2024
22

2024 HIV Mid-Year Market Memo
Introducing the eighth edition of CHAI’s HIV Mid-Year Market Memo, a brief that covers the latest trends in the HIV space in low- and...
Jul 17, 2024
72

Planning Considerations for the Introduction of pALD
This slide deck, presented by CHAI at IPHASA 2023, outlines planning considerations for the introduction of pALD throughout all stages of...
Dec 14, 2023
267

2023 HIV Market Report
CHAI is pleased to release the fourteenth issue of our annual HIV market report. This report provides a detailed look at the complex,...
Nov 1, 2023
30

Pediatric Treatment Optimization Roadmap
This treatment optimization roadmap is a resource for Ministries of Health and partner organizations. It offers a summary of pediatric...
Oct 20, 2023
277

Pediatric DRV/r (pDRV/r) FAQs
This document is meant to answer some of the most common questions that surround pediatric darunavir/ritonavir 120/20mg (pDRV/r) - a new...
Sep 6, 2023
169

Pediatric DRV/r (pDRV/r) Product Profile
This product profile provides a clinical overview of the best-in-class protease inhibitor (PI) formulated in a fixed-dose combination...
Sep 6, 2023
169

2023 CHAI HIV Mid-Year Market Memo
Introducing the seventh edition of CHAI’s HIV Mid-Year Market Memo, a brief that covers the latest trends in the HIV space in low- and...
Jun 7, 2023
111

Pediatric ALD (pALD) FAQs
This document is meant to answer some of the most common questions surround the fixed-dose combination of pediatric...
Jun 5, 2023
302

pALD Product Profile
This product profile provides a clinical overview of the fixed-dose combination of pediatric abacavir/lamivudine/ dolutegravir 60/30/5 mg...
May 30, 2023
1,330

GAP-f pALD Introduction and Rollout Planning Considerations for National Programmes
The GAP-f pDTG task team has developed a brief outlining product introduction and rollout considerations for national programmes when...
May 24, 2023
601

The Transitioning Children to Optimal Regimens of Paediatric Dolutegravir (TORPEDO) Study
The Transitioning children to Optimal Regimens of Paediatric Dolutegravir (TORPEDO) Study was conducted in Benin, Nigeria, and Uganda....
May 4, 2023
263

2022 HIV Market Report
CHAI is pleased to release the 13th issue of our annual HIV market report. This report provides a detailed look at the complex,...
Dec 16, 2022
130

2022 CHAI HIV Mid-Year Market Memo
Introducing the sixth edition of CHAI’s HIV Mid-Year Market Memo, a brief that covers the latest trends in the HIV space in low- and...
May 31, 2022
225

GAP-f pDTG Implementation Considerations for National Programmes
In mid-2021, national HIV programmes began to transition treatment for children living with HIV to dolutegravir (DTG) 10 ...
May 24, 2022
372

Adult DRV/r (400/50mg) FAQs for Communities and PLHIV
CHAI developed these frequently asked questions (FAQs) to lay out information for communities and PLHIV on the subject of DRV/r (400/50...
Apr 13, 2022
230

Adult DRV/r (400/50mg) Clinical Action Memo
Darunavir (DRV) is a best-in-class protease inhibitor (PI) used in combination with other antiretroviral (ARV) drugs for the...
Mar 17, 2022
318

CHAI DRV/r 2L Product Profile
A presentation with the latest information on DRV/r (400/50mg) and considerations for adult second line treatment optimization.
Mar 17, 2022
175

DRV/r (400/50mg) FAQs
CHAI developed these frequently asked questions (FAQs) to lay out information for national HIV programs considering the adoption and...
Mar 17, 2022
91

2021 Regional HIV Market Briefs
Regional HIV Market Briefs, produced by the CHAI HIV Access Program, provide the latest region-specific market intelligence on ART...
Nov 16, 2021
35
bottom of page